Beranda › Penyakit Crohn › Texas › Tyler
Uji klinis Penyakit Crohn di Tyler, TX
16 studi untuk Penyakit Crohn mencari peserta di lokasi sekitar Tyler (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Menerima pesertaFase 3
- Tyler Research Institute ( Site 0294), Tyler
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Menerima pesertaFase 3
- Tyler Research Institute ( Site 5001), Tyler
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Menerima pesertaFase 2
- Tyler Research Institute /ID# 265545, Tyler
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Menerima pesertaFase 3
- The University of Texas Health Science Center at Tyler, Tyler
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Menerima pesertaFase 2/3
- Tyler Research Institute, LLC, Tyler
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Menerima pesertaFase 2
- Tyler Research Institute, LLC, Tyler
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Menerima pesertaFase 3
- Tyler Research Institute, Tyler
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Menerima pesertaFase 3
- Tyler Research Institute, LLC-Site Number: 8400095, Tyler
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Menerima pesertaFase 3
- Tyler Research Institute LLC-Site Number: 8400095, Tyler
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Menerima pesertaFase 2
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Menerima pesertaFase 4
- Tyler Research Institute, LLC, Tyler
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Menerima pesertaFase 3
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Menerima pesertaFase 3
- Tyler Research Institute, LLC, Tyler
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Menerima pesertaFase 2
- Tyler Research Institute, LLC, Tyler
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Menerima pesertaFase 2
- Tyler Research Institute, LLC, Tyler
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Menerima pesertaFase 2
- Mirador Therapeutics Selected Site, Tyler
Uji klinis Penyakit Crohn di kota lain
- New York City, NY35 studi
- Cleveland, OH19 studi
- St. Louis, MO19 studi
- Boston, MA19 studi
- Miami, FL19 studi
- Orlando, FL17 studi
- Houston, TX17 studi
- Atlanta, GA17 studi
- San Diego, CA15 studi
- San Antonio, TX15 studi
- Los Angeles, CA15 studi
- Philadelphia, PA13 studi
Studi lain di Tyler
- Kanker Paru Non-Sel Kecil20 studi
- Kolitis Ulseratif14 studi
- Kanker Kolorektal8 studi
- Gagal Jantung8 studi
- Kanker (semua jenis)7 studi
- Kanker Ovarium7 studi
- Kanker Endometrium6 studi
- Karsinoma Sel Skuamosa Kepala dan Leher6 studi
- Kanker Payudara6 studi
- Kanker Metastatik5 studi
- Penyakit Radang Usus5 studi
- Leukemia Limfositik Kronis5 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.